Patents by Inventor Camille Locht

Camille Locht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210290667
    Abstract: A method of reducing or preventing the development of airway inflammation in a subject includes the step of infecting the respiratory tract of a subject an amount of a composition including a pharmaceutically acceptable carrier and live attenuated pertactin-deficient Bordetella bacteria sufficient to colonize the respiratory tract of the subject. The step of infecting the subject with the live attenuated pertactin-deficient Bordetella bacteria results in reduction or prevention of the development of airway inflammation in the subject.
    Type: Application
    Filed: June 2, 2021
    Publication date: September 23, 2021
    Inventors: Luis Solans, Camille Locht, Anne Tsicopoulos, Saliha Ait-Yahia Sendid
  • Patent number: 11110161
    Abstract: The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: September 7, 2021
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Patent number: 11065276
    Abstract: A method of reducing or preventing the development of airway inflammation in a subject includes the step of infecting the respiratory tract of a subject an amount of a composition including a pharmaceutically acceptable carrier and live attenuated pertactin-deficient Bordetella bacteria sufficient to colonize the respiratory tract of the subject. The step of infecting the subject with the live attenuated pertactin-deficient Bordetella bacteria results in reduction or prevention of the development of airway inflammation in the subject.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: July 20, 2021
    Inventors: Luis Solans, Camille Locht, Anne Tsicopoulos, Saliha Ait-Yahia Sendid
  • Publication number: 20200323901
    Abstract: A method of reducing or preventing the development of airway inflammation in a subject includes the step of infecting the respiratory tract of a subject an amount of a composition including a pharmaceutically acceptable carrier and live attenuated pertactin-deficient Bordetella bacteria sufficient to colonize the respiratory tract of the subject. The step of infecting the subject with the live attenuated pertactin-deficient Bordetella bacteria results in reduction or prevention of the development of airway inflammation in the subject.
    Type: Application
    Filed: April 30, 2020
    Publication date: October 15, 2020
    Inventors: Luis Solans, Camille Locht, Anne Tsicopoulos, Saliha Ait-Yahia Sendid
  • Publication number: 20200297833
    Abstract: A Fim3-producing BPZE1 derivative with sufficiently stable fim3 expression to provide improved protection in mice against Fim3-only producing clinical B. pertussis isolates was developed. The fim3 expression in BPZElf3 did not alter the protective efficacy against Fim2+ strains, nor against strains that produce neither Fim2 nor Fim3.
    Type: Application
    Filed: April 14, 2020
    Publication date: September 24, 2020
    Inventors: Anne-Sophie Debrie, Dominique Raze, Camille Locht
  • Publication number: 20200282041
    Abstract: The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Application
    Filed: April 3, 2020
    Publication date: September 10, 2020
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Patent number: 10682377
    Abstract: A method of reducing or preventing the development of airway inflammation in a subject includes the step of infecting the respiratory tract of a subject an amount of a composition including a pharmaceutically acceptable carrier and live attenuated pertactin-deficient Bordetella bacteria sufficient to colonize the respiratory tract of the subject. The step of infecting the subject with the live attenuated pertactin-deficient Bordetella bacteria results in reduction or prevention of the development of airway inflammation in the subject.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: June 16, 2020
    Assignees: Institut Pasteur de Lille, INSTITUT NATIONAL DE LA SANTÉET DE LA RECHERCHE MÉDICALE
    Inventors: Luis Solans, Camille Locht, Anne Tsicopoulos, Saliha Ait-Yahia Sendid
  • Publication number: 20200171139
    Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
    Type: Application
    Filed: February 11, 2020
    Publication date: June 4, 2020
    Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
  • Patent number: 10653765
    Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: May 19, 2020
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Patent number: 10610580
    Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: April 7, 2020
    Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
  • Publication number: 20190358309
    Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Application
    Filed: August 9, 2019
    Publication date: November 28, 2019
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Patent number: 10420827
    Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: September 24, 2019
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur de Lille, National University of Ireland Maynooth
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanaugh
  • Patent number: 10369207
    Abstract: A CyaA-deficient B. pertussis mutant was constructed and used in a vaccine. The pertussis-specific antibody profile and Th17 response induced by vaccination with the mutant was surprisingly comparable to that induced by B. pertussis strains not deficient in CyaA.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: August 6, 2019
    Assignees: National University of Singapore, Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur de Lille
    Inventors: Sylvie Claudette Alonso, Annabelle Rui Fen Lim, Camille Locht
  • Publication number: 20190175719
    Abstract: A mutated Bordetella strain comprising at least a mutated ptr gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
    Type: Application
    Filed: February 18, 2019
    Publication date: June 13, 2019
    Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
  • Patent number: 10258681
    Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: April 16, 2019
    Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
  • Publication number: 20180339035
    Abstract: A CyaA-deficient B. pertussis mutant was constructed and used in a vaccine. The pertussis-specific antibody profile and Th17 response induced by vaccination with the mutant was surprisingly comparable to that induced by B. pertussis strains not deficient in CyaA.
    Type: Application
    Filed: July 12, 2018
    Publication date: November 29, 2018
    Inventors: Sylvie Claudette Alonso, Rui Fen, Annabelle Lim, Camille Locht
  • Publication number: 20180305416
    Abstract: Recombinant Mycobacteria (rMyc) which contain sequences encoding a heparin-binding hemagglutinin (HBHA) fission protein are provided, as are methods of making and using the rMyc and the fusion protein. The fusion protein includes an amino terminal mycobacterial antigen Ag85B leader peptide and transcription of the fusion protein is driven by an Ag85B promoter sequence. The recombinant fusion protein is produced in abundance by the rMyc, is post-translationally methylated, and is highly antigenic.
    Type: Application
    Filed: November 30, 2017
    Publication date: October 25, 2018
    Inventors: John Fulkerson, Michael Brennan, Kamalakannan Velmurugan, Camille Locht
  • Patent number: 10046044
    Abstract: A CyaA-deficient B. pertussis mutant was constructed and used in a vaccine. The pertussis-specific antibody profile and Th17 response induced by vaccination with the mutant was surprisingly comparable to that induced by B. pertussis strains not deficient in CyaA.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: August 14, 2018
    Assignees: National University of Singapore, Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur de Lille
    Inventors: Sylvie Claudette Alonso, Rui Fen Annabelle Lim, Camille Locht
  • Publication number: 20180085450
    Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Application
    Filed: November 1, 2017
    Publication date: March 29, 2018
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanagh
  • Patent number: 9926346
    Abstract: Recombinant Mycobacteria (rMyc) which contain sequences encoding a heparin-binding hemagglutinin (HBHA) fusion protein are provided, as are methods of making and using the rMyc and the fusion protein. The fusion protein includes an amino terminal mycobacterial antigen Ag85B leader peptide and transcription of the fusion protein is driven by an Ag85B promoter sequence. The recombinant fusion protein is produced in abundance by the rMyc, is post-translationally methylated, and is highly antigenic.
    Type: Grant
    Filed: April 16, 2012
    Date of Patent: March 27, 2018
    Assignees: Aeras, Institut National De La Sante Et De La Recherche Medicale (Inserm)
    Inventors: John Fulkerson, Michael Brennan, Kamalakannan Velmurugan, Camille Locht